


# **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application:

1. **(Currently Amended)** A compound of formula I:



**I**


wherein, independently for each occurrence,

L is a bond or L is alkyl, alkenyl, or cycloalkyl which may be substituted with one or more R<sub>1</sub>;

A is a monocyclic ring of 4-7 atoms containing 0-2 heteroatoms, a bicyclic ring of 8-12 atoms containing 0-4 heteroatoms or a tricyclic ring of 12-16 atoms containing 0-6 heteroatoms wherein the rings are independently aliphatic, aromatic, heteroaryl, or heterocyclic; wherein the heteroatoms selected from N, S, and O, and wherein the rings are optionally substituted with one or more groups selected from C<sub>1-4</sub> alkyl, CH<sub>2</sub>OH, OR'', SR'', CN, N(R'')<sub>2</sub>, CH<sub>2</sub>N(R'')<sub>2</sub>, NO<sub>2</sub>, CF<sub>3</sub>, CO<sub>2</sub>R'', CON(R'')<sub>2</sub>, COR'', NR''C(O)R'', F, Cl, Br, I and -S(O)CF<sub>3</sub>, wherein R'' is H, alkyl or alkaryl;

R<sub>1</sub> is, independently for each occurrence, H, alkyl, cycloalkyl, aryl, or alkaryl;

R<sub>2</sub> is



wherein, independently for each occurrence,

B is a bond, C(R<sub>1</sub>)<sub>2</sub> or C=O;

~~E is O or S;~~

D is C(R<sub>1</sub>)<sub>2</sub>, NR<sub>1</sub>, C=O,  
 providing that the two Ds are different;

J is NR<sub>1</sub>, CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>, or O;

~~M is CR<sub>1</sub> or N;~~

Q is N or CH;

~~U is O, H<sub>3</sub>, or CH<sub>3</sub>;~~

X is H, C<sub>1-4</sub> alkyl, CH<sub>2</sub>OH, OR<sub>1</sub>, SR<sub>1</sub>, CN, N(R<sub>1</sub>)<sub>2</sub>, CH<sub>2</sub>N(R<sub>1</sub>)<sub>2</sub>, NO<sub>2</sub>, CF<sub>3</sub>, CO<sub>2</sub>R<sub>1</sub>,

CON(R<sub>1</sub>)<sub>2</sub>, COR<sub>1</sub>, NR<sub>1</sub>C(O)R<sub>1</sub>, F, Cl, Br, I, -S(O)<sub>2</sub>CF<sub>3</sub>,  
 or

r is 0, 1, or 2;

~~R<sub>6</sub> is C(O)OR<sub>1</sub>;~~


R<sub>1</sub> is as previously defined;

b is an integer from 0-4;

~~R<sub>3</sub> is alkyl or cycloalkyl; and~~

~~a is an integer from 0-4; and~~

~~Y<sub>1</sub> is~~



~~wherein,~~

$R_4$  is a water solubilizing group;

$R_3$  is H, alkyl, or cycloalkyl; and


$n$  is an integer from 0 to 4;

or a pharmaceutically acceptable salt thereof.


2. **(Original)** The compound of claim 1, wherein L is a  $C_2$  alkenyl.

3-4. **(Canceled)**

5. **(Original)** The compound of claim 1, wherein L is a  $C_2$  alkenyl and  $R_2$  is wherein  $R_1$  is H.



6. **(Original)** The compound of claim 1, wherein L is a  $C_2$  alkenyl and  $R_2$  is wherein  $R_1$  is H and the D adjacent to B is  $NR_1$ .



7-12. **(Canceled)**

13. **(Original)** The compound of claim 1, wherein A is a 9 membered bicyclic heteroaryl.

14. **(Original)** The compound of claim 1, wherein A comprises at least 1 heteroatom.

15-16. **(Canceled)**

17. **(Original)** The compound of claim 1, wherein A comprises at least 1 oxygen atom.

18.-23. **(Canceled)**

24. **(Original)** A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or excipient.

25. **(Currently Amended)** The composition of claim 24, wherein the composition pharmaceutically acceptable carrier is suitable ~~is formulated~~ for intravenous or injectable, administration.

26.-30. **(Canceled)**

31. **(Currently Amended)** A tablet comprising the composition of claim 24, The composition of claim 30, wherein the composition is formulated in tablets such that the amount of compound provided in 20 tablets, if taken together, provides a dose of at least the ED<sub>50</sub> but no more than ten times the ED<sub>50</sub>.
- 32.-33. **(Canceled)**
34. **(Currently Amended)** A pill for reducing bacterial levels in a subject with a bacteria related illness, comprising a compound of claim 53 ~~4~~.
- 35.-48. **(Canceled)**
49. **(Original)** A kit comprising the pharmaceutical composition of claim 24 and instructions for use thereof.
50. **(Previously Presented)** The compound of claim 6, wherein B is CH<sub>2</sub>.
51. **(Previously Presented)** The compound of claim 50, wherein A comprises a nine-membered bicyclic heteroaryl comprising at least one O.
52. **(Canceled)**
53. **(Previously Presented)** The compound (E)-3-(3,3-Dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-c][1,4]diazepin-7-yl)-N-methyl-N-(3-methyl-benzofuran-2-ylmethyl)acrylamide, or pharmaceutically acceptable salts thereof.
54. **(New)** A pharmaceutically acceptable composition comprising the compound of claim 53, and a pharmaceutically acceptable carrier.